신고사유
신고해주신 내용은 쇼핑몰 운영자의 검토 후 내부 운영 정책에 의해 처리가 진행됩니다.
Brief Description | An FDA-approved immunosuppressive drug, a novel inhibitor of the Aβ-ABAD interaction (IC50 = 200 lM) |
---|---|
Appearance | Solid powder |
Synonyms | LY 53616; LY53616; LY-53616; Frentizole; 1-(6-methoxy-1,3-benzothiazol-2-yl)-3-phenylurea; 7EY946394I; frentizole; mono-hydrate of frentizole; FRENTIZOLE; 26130-02-9; Frentizol; Compound 53616; MLS000555007; CHEMBL128988; UNII-7EY946394I; 1-(6-methoxy-1,3-benzothiazol-2-yl)-3-phenylurea; NCGC00160657-01; SMR000147124; 1-(6-Methoxy-benzothiazol-2-yl)-3-phenyl-urea; DSSTox_CID_26279; DSSTox_RID_81505; 1-(6-methoxybenzo[d]thiazol-2-yl)-3-phenylurea; DSSTox_GSID_46279; CAS-26130-02-9; Frentizolum; Frenazole; AC1Q4EVH; Frentizole (USAN/INN); Opera_ID_1653; Frentizol [INN-Spanish]; Frentizolum [INN-Latin]; AC1L1PF2; Oprea1_516941; cid_33334; MLS001201824; Bio-0413; Frentizole [USAN:INN:BAN]; SCHEMBL599582; DTXSID5046279; HMS2233G12; HMS3370C02; ZINC8994439; Tox21_111964; 3684AH; BDBM50189352; STK078558; ZINC08994439; AKOS001049350; Tox21_111964_1; 7EY946394I; CS-0841; MCULE-7561551977; NCGC00160657-03; AK468739; DR001179; HE329695; HY-15374; LY 53616; ST50103599; 1-(6-Methoxy-2-benzothiazolyl)-3-phenylurea; 1-(6-methoxybenzothiazol-2-yl)-3-phenylurea; D00159; W-5046; Urea, N-(6-methoxy-2-benzothiazolyl)-N'-phenyl-; 3-(6-methoxy-1,3-benzothiazol-2-yl)-1-phenylurea; N-(6-methoxybenzothiazol-2-yl)(phenylamino)carboxamide; T0510-0233 |
Solubility | DMSO: ≥ 3 mg/mL |
Storage | Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -22℃ for long term (months to years). |
Application | Anti-Alzheimer agents; Amyloid-β inhibitor |
게시물이 없습니다
게시물이 없습니다